Topelia at BIO 2024: Showcasing Innovation and Advancing Coronavirus Therapy

Topelia Australia helped represent Australian ingenuity in June at the BIO 2024 Conference in San Diego, where the peak of the global biotech industry held their annual gathering. During the event, Dr. David Fox, Managing Director and CEO of Topelia, sat down with Stuart Dignam from the MTPConnect Podcast to discuss Topelia’s pioneering work in developing the triple therapy - designated TPL101 - for coronavirus infection.

The proprietary treatment which combines Ivermectin, Doxycycline, and zinc leverages the synergistic effects of these components to deliver enhanced antiviral and anti-inflammatory outcomes for patients. While Ivermectin has previously been a polarising drug in public debate, Topelia’s formulation is based on rigorous research and received a very warm reception from a range of delegates including the US Department of Defence.

Stuart and David discussed the ongoing development of Topelia’s triple therapy TPL101. David outlined how Topelia has already completed much of the pre-clinical work, which has definitively shown antiviral and anti-inflammatory effects. The company is advancing its Phase 1 trials and is preparing for a Phase 3 trial for which already has ethics approval in place. Each of these studies is being conducted to meet the high standards required by regulatory bodies, including the TGA (Therapeutic Goods Administration), FDA, and EMA, positioning Topelia for rapid international expansion.

BIO 2024 offered more than just a platform to showcase innovation; it facilitated invaluable connections. Through the efforts of MTPConnect, Investment NSW, and NSW Health, the Australian delegation was introduced to key pharmaceutical groups and potential partners. For Topelia, these interactions are helping shape the development and refinement of their product. The feedback from industry leaders is crucial as the company navigates the regulatory landscape and prepares for discussions with the FDA, including pre-IND (Investigational New Drug) discussions.

As a public unlisted company backed by high-net-worth individuals, Topelia benefits from a stable and patient financial foundation, allowing it to focus on product development. Professor Barody’s reputation and expertise played a pivotal role in securing capital for the company’s ambitious goals.

Following the success of BIO 2024, Topelia was invited to join a post-conference panel hosted by King & Wood Mallesons. Alongside industry leaders, Dr. David Fox discussed the support provided by Investment NSW and NSW Health through the #GoingGlobal program, reflecting on the opportunities and insights gained during the event.

BIO 2024 marked an important milestone for Topelia Australia, solidifying its role as a leader in developing innovative antiviral treatment and further expanding its reach in the global biotech landscape.

For more information contact Topelia via the contact web page.

Bio International Convention